Introduction {#Sec1}
============

Obstructive sleep apnea syndrome (OSAS) is characterized by repetitive complete or partial occlusions of the upper airway with persistent inspiratory efforts during sleep, followed by oxyhemoglobin desaturations and terminated by arousals. OSAS is a public health burden because of its medical and socioeconomic consequences, including a higher likelihood of vehicle crashes and occupational accidents, increased risk of cardiovascular diseases, neurocognitive dysfunction, and impaired quality of life \[[@CR1]\].

The gold standard treatment for OSAS is continuous positive airway pressure (CPAP), which has been shown to reduce sleepiness \[[@CR2]\] and road accidents \[[@CR3]\], and might decrease cardiovascular risk and mortality \[[@CR4]\]. However, compliance with CPAP is an issue in up to half of all users \[[@CR5]\], potentially limiting its effectiveness \[[@CR6]\]. Mandibular repositioning devices (MRDs) enlarge the upper airway during sleep by holding the mandible in a forward position and are an effective alternative to CPAP, particularly in mild-to-moderate OSA or in patients not adherent to or refusing CPAP \[[@CR7]\]. Reductions in the apnea-hypopnea index (AHI) during MRD therapy are usually smaller than those during CPAP, but patient acceptability and compliance may be better, with similar quality of life and symptom benefits \[[@CR8]\].

The reported prevalence of OSAS is generally lower in women vs. men, and there are a number of sex-related differences in disease manifestation and presentation \[[@CR1]\]. Mechanisms underlying sex differences in OSAS prevalence are not fully understood \[[@CR9], [@CR10]\], and there is a relative lack of data on sex differences in the response to OSA therapies, particularly MRDs.

The prospective ORthèse d'avanCée mAndibulaire type O.R.M dans le traitement en DEuxième intention du SAHOS sévère (ORCADES) cohort study is investigating the long-term efficacy and tolerability of a computer-aided design (CAD)/computer-aided manufacturing (CAM) MRD in OSA patients non-compliant with or intolerant of CPAP. Interim short-term results showed that MRD treatment was effective across all severities of OSAS, and univariate logistic regression analysis of factors predicting efficacy indicated better MRD efficacy in women than in men (hazard ratio 2.12, 95% confidence interval 1.21--3.73; *p* = 0.0078), although this did not persist in multivariate analysis \[[@CR11]\]. This post hoc analysis of the ORCADES study compared CAD/CAM MRD efficacy in men and women after 3--6 months follow-up.

Methods {#Sec2}
=======

Study design and oversight {#Sec3}
--------------------------

The prospective, observational ORCADES study (NCT01326143) was conducted at 28 centers in France. The study design and details of MRD devices have been described in detail previously \[[@CR11]\]. The Steering Committee (SC) defined the study design and was responsible for the clinical and scientific conduct of the study and publication of the results. C.R.O. Clinact (France) performed the data collection, quality control, management, and analysis. The SC had full access to all data and takes responsibility for the integrity and accuracy of the analysis.

Patients {#Sec4}
--------

Eligible patients had newly diagnosed mild-to-moderate (AHI 5--30/h) or severe (AHI \> 30/h) OSAS, excessive daytime sleepiness (Epworth Sleepiness Scale (ESS) score \> 10), and refusal of or non-compliance with CPAP. Exclusion criteria included previous MRD treatment, contraindications to MRD therapy, central apnea index \> 5/h, severe sleep comorbidities other than OSAS, and coexisting psychiatric disease.

MRD titration and follow-up {#Sec5}
---------------------------

Patients were fitted with a CAD/CAM MRD (Narval CC™; ResMed). Mandibular advancement was gradually adjusted at the discretion of the dental sleep specialist (over a 15-mm range) until the best benefit-risk ratio between symptom resolution and tolerability was achieved. At titration visits, patients reported the degree of improvement (none, some, important) in three symptoms (snoring, fatigue, and sleepiness) and also rated tolerability (based on articular, dental, and periodontal pain) on a non-graduated, 10-cm visual analogue scale.

Assessments and endpoints {#Sec6}
-------------------------

The primary endpoint was treatment success (proportion of patients with a ≥ 50% decrease in AHI from baseline to follow-up). Complete response was defined using a range of AHI cut-off values (\< 5/h, \< 10/h, \< 15/h).

At baseline and follow-up visits, self-reported clinical symptoms were assessed, sleep quality, subjective sleepiness was scored using the ESS, quality of life using the Quebec Sleep Questionnaire (QSQ) and fatigue using the Pichot scale \[[@CR11]\].

Sleep and/or nocturnal respiratory parameters were recorded at baseline and after 3 months with the same polygraphy (PG) or polysomnography (PSG) device used to diagnose OSA. If AHI decreased by \< 50% and/or symptoms persisted, PSG/PG was performed again at 6 months after additional mandibular advancements. PSG/PG recordings were manually scored using American Academy of Sleep Medicine guidelines \[[@CR12]\]. Positional OSA was defined when the supine AHI was at least twice that in other positions and AHI was \> 10/h \[[@CR13]\].

Self-reported MRD compliance (hours/night; nights/week) was reported at each follow-up visit, and comprehensive data on MRD-related side effects were collected*.* Side effect severity and impact on MRD treatment was determined by sleep and dental sleep physicians.

Statistical analysis {#Sec7}
--------------------

Quantitative changes from baseline to follow-up were presented as mean ± standard deviation and compared using unpaired or paired Student's *t* test or nonparametric test according to normality of distribution and group comparison. Qualitative changes were described using frequency distribution and compared using Fisher Exact or chi-square test. Comparisons between men and women were assessed using Student's *t* test, ANOVA, or Wilcoxon-Mann-Whitney test. Three logistic models were created and backward stepwise regression analysis was used to determine independent factors associated with therapy success and complete response, model 1: all patients; model 2: men; and model 3: women. For all models, variables with a *p* value \< 0.10 in the univariate analysis were entered in the stepwise logistic regressions, and variables with a *p* value \< 0.05 were retained in the final models. For model 1, univariate analysis on the interaction between gender and potential predictive factors was also performed. Statistical analyses were performed using SAS version 9.

Results {#Sec8}
=======

Study population {#Sec9}
----------------

A total of 515 eligible OSA patients (144 women, 371 men) were screened between May 2011 and September 2013; 154 with contraindications to MRD therapy or treatment with another MRD or who declined to participate were excluded. Therefore, 312 eligible patients (77 women, 235 men) were enrolled in our cohort study. Of these, 52 patients withdrew from the study before evaluation of the endpoint criteria, leaving 260 available for follow-up analysis (Fig. [1](#Fig1){ref-type="fig"}). There were significantly fewer women than men in the study population and there were a number of statistically significant between-group differences (Table [1](#Tab1){ref-type="table"}). Women were older; had a lower body mass index (BMI), neck and waist circumference, and diastolic blood pressure; were more likely to have retrognathia, hypothyroidism, and positional OSA; and had a lower apnea index (AI) and non-supine AHI vs. men (Table [1](#Tab1){ref-type="table"}). Women and men reported similar MRD use (6.7 and 6.6 h/night on 6.8 and 6.5 nights/week, respectively). Device use every night was reported by 85% of women and men, and device use ≥ 4 h/night on ≥ 4 days/week by 100% of women and 94% of men. Women and men required a similar number of titration visits to optimize MRD efficacy (1.8 ± 1.2), with similar final mean mandibular advancement (6.8 ± 2.2 vs. 7.4 ± 2.1 mm; *p* = 0.07) and percentage of maximal mandibular advancement (median (Q1, Q3) 76.4% (66.7, 100) vs. 83.3% (66.7, 100); *p* = 0.26).Fig. 1ORCADES study flow chart. *CAD/CAM* computer-aided design/computer-aided manufacturing, *FU* follow-up, *m* men, *MRD* mandibular repositioning device, *w* womenTable 1Baseline characteristics by patient sex*N* = 312WomenMen*p* valueNumber (%)77 (24.7)235 (75.3)\< 0.0001Age, years56.8 ± 10.252.1 ± 11.20.0013Body mass index, kg/m^2^26.7 ± 5.427.2 ± 3.50.032Obese, *N* (%)17 (22.1)44 (18.7)NSWaist circumference, cm90.5 ± 13.498.9 ± 11.2\< 0.0001Neck circumference, cm35.6 ± 3.141.0 ± 3.1\< 0.0001Retrognathia, *N* (%)33 (42.9)47 (20)0.0006Maximum mandibular advancement, mm8.7 ± 2.58.9 ± 2.4NSNo previous CPAP therapy, *N* (%)45 (58.4)107 (45.7)NSSystolic blood pressure, mmHg124.7 ± 13.1127.6 ± 11.2NSDiastolic blood pressure, mmHg74.6 ± 10.278.9 ± 9.70.0032Comorbidities, *N* (%) Arterial hypertension25 (32.5)69 (29.4)NS Diabetes5 (6.5)16 (6.8)NS Hypothyroidism11 (14.3)4 (1.7)\< 0.0001 Stroke3 (3.9)4 (1.7)NS Restless leg syndrome0 (0)4 (1.7)NSRespiratory parameters Mean AHI, /h26.5 ± 13.730.1 ± 15.1NS Mild OSA (AHI 5--15/h), *N* (%)14 (18.2)35 (14.9)NS Moderate OSA (AHI 15--30/h), *N* (%)37 (48.1)94 (40.0)NS Severe OSA (AHI \> 30/h), *N* (%)26 (33.8)106 (45.1)0.08 Supine AHI, /h32.2 ± 17.938.5 ± 23.2NS Non-supine AHI, /h13.1 ± 15.319.6 ± 17.90.0038 Positional OSA, *N* (%)45 (58)82 (35)0.0026 AI, /h9.2 ± 9.013.8 ± 13.00.0044 HI, /h17.2 ± 10.116.4 ± 9.7NS cAI, /h0.3 ± 0.80.5 ± 1.0NS SpO~2~, %93.8 ± 1.993.7 ± 1.9NS Minimum SpO~2~, %83.0 ± 6.881.3 ± 8.0NS Time with SpO~2~ \< 90%, min21.0 ± 32.126.5 ± 55.7NS ODI, /h21.8 ± 19.321.7 ± 18.1NS Snoring, /h108 ± 146143 ± 276NS Snoring duration, % TRT27%29%NS*AHI* apnea-hypopnea index, *AI* apnea index, *cAI* central apnea index, *CPAP* continuous positive airway pressure, *HI* hypopnea index, *NREM* non-rapid eye movement, *NS* not significant, *ODI* oxygen desaturation index, *OSA* obstructive sleep apnea, *REM* rapid eye movement, *SpO2* oxygen saturationValues are mean ± standard deviation, or number of patients (%)

Primary endpoint: MRD efficacy {#Sec10}
------------------------------

Overall treatment success and complete response rates were significantly higher in women than in men (Fig. [2](#Fig2){ref-type="fig"}), primarily due to significant sex differences in the subgroup with severe OSA (success rate 100% in women vs. 67.7% in men, *p* = 0.0015; complete response at AHI \< 5/h, \< 10/h, and \< 15/h in 49 vs. 34.0% (*p* = 0.0052), 78 vs. 62%(*p* = 0.016), and 92 vs. 76% (*p* = 0.0032), respectively).Fig. 2Mandibular repositioning device efficacy in men and women at 3- to 6-month follow-up. *AHI* apnea-hypopnea index, *Success rate* percentage of patients with a ≥ 50% decrease in AHI from baseline to follow-up

Secondary endpoints: sleep and respiratory parameters {#Sec11}
-----------------------------------------------------

There was a significant reduction in mean AHI, irrespective of sex (Table [2](#Tab2){ref-type="table"}), again due to a significantly greater reduction in the severe OSA subgroup (Table [3](#Tab3){ref-type="table"}). Mean AI, hypopnea index (HI), supine and non-supine AHI, nadir oxygen saturation (SpO~2~), and time with SpO~2~ \< 90% decreased significantly from baseline to follow-up in men and women (Table [2](#Tab2){ref-type="table"}), with the greatest decrease in HI seen in women with severe OSA (Table [3](#Tab3){ref-type="table"}).Table 2Changes in respiratory parameters during MRD therapy by patient sexBaselineFollow-upDifference*p* valuevs. BaselineMen vs. womenAHI, /h Women26.5 ± 13.76.5 ± 5.4− 19.3 ± 11.7\< 0.0001NS Men30.1 ± 15.111.6 ± 13.2− 18.7 ± 12.6\< 0.0001AI, /h Women9.2 ± 9.01.4 ± 2.3− 7.5 ± 8.4\< 0.00010.084 Men13.8 ± 13.04.5 ± 9.2− 9.7 ± 10.7\< 0.0001HI, /h Women17.2 ± 10.15.1 ± 4.4− 11.4 ± 8.7\< 0.0001NS Men16.4 ± 9.747.2 ± 7.73− 9.0 ± 10.4\< 0.0001Supine AHI, /h Women32.2 ± 17.97.6 ± 6.8− 22.7 ± 15.7\< 0.0001NS Men38.5 ± 23.213.8 ± 17.81− 24.3 ± 23.0\<0.0001Non-supine AHI, /h Women13.1 ± 15.34.0 ± 4.7− 8.9 ± 15.70.0075NS Men19.6 ± 17.97.1 ± 12.2− 12.5 ± 14.9\< 0.0001Mean SpO~2~, % Women93.8 ± 1.994.0 ± 1.90.1 ± 1.5NSNS Men93.7 ± 1.993.9 ± 1.920.2 ± 1.8NSNadir SpO~2~, % Women83.0 ± 6.885.3 ± 8.92.3 ± 9.0\< 0.0001NS Men81.3 ± 8.084.6 ± 8.93.3 ± 9.9\< 0.0001SpO~2~ \< 90%, min Women21.0 ± 32.110.7 ± 22.8− 7.3 ± 29.20.0018NS Men26.5 ± 55.718.0 ± 52.7− 9.1 ± 57.3\< 0.0001ODI, /h Women21.8 ± 19.36.7 ± 6.1− 14.1 ± 16.1\< 0.0001NS Men21.7 ± 18.110.3 ± 12.9− 11.7 ± 18.7\< 0.0001Time in supine position, min Women230 ± 108221 ± 132− 51 ± 990.0160.0053 Men187 ± 108205 ± 11018 ± 1180.07Time in non-supine position, min Women194 ± 135201 ± 12335 ± 92NS0.027 Men236 ± 115217 ± 114− 25 ± 1240.07Values are mean ± standard deviation*AHI* apnea-hypopnea index, *AI* apnea index, *HI* hypopnea index, *NS* not significant, *ODI* oxygen desaturation index, *SpO2* oxygen saturationTable 3Change in respiratory parameters during MRD therapy by patient sex and sleep apnea severityNumberBaselineNumberFollow-upDifference*p* valueVs. baselineMen vs. womenAHI, /h Women, mild-to-moderate OSA5118.9 ± 7.3486.5 ± 5.4− 19.3 ± 11.7\< 0.0001NS Men, mild-to-moderate OSA12919.4 ± 6.311411.6 ± 13.20− 18.7 ± 12.6\< 0.0001 Women, severe OSA2641.4 ± 10.5228.7 ± 6.37− 32.2 ± 8.2\< 0.00010.011 Men, severe OSA10643.2 ± 12.19618.3 ± 16.25− 25.0 ± 14.8\< 0.0001AI, /h Women, mild-to-moderate OSA506.2 ± 6.1471.3 ± 2.6− 4.6 ± 5.8\< 0.0001NS Men, mild-to-moderate OSA1297.1 ± 5.81141.6 ± 2.9− 5.5 ± 5.2\< 0.0001 Women, severe OSA2615.1 ± 10.7221.8 ± 1.5− 13.4 ± 10.0\< 0.0001NS Men, severe OSA10621.8 ± 14.6967.9 ± 12.5− 14.7 ± 13.2\< 0.0001HI, /h Women, mild-to-moderate OSA5012.9 ± 6.7474.2 ± 3.3− 8.7 ± 6.4\< 0.0001NS Men, mild-to-moderate OSA12912.3 ± 6.91144.5 ± 4.2− 7.9 ± 7.6\< 0.0001 Women, severe OSA2625.4 ± 10.6226.9 ± 5.7− 17.2 ± 10.1\< 0.00010.026 Men, severe OSA10621.3 ± 10.49610.4 ± 9.5− 10.4 ± 12.9\< 0.0001Supine AHI, /h Women, mild-to-moderate OSA3724.7 ± 11.9426.8 ± 5.5− 18.0 ± 12.4\< 0.0001NS Men, mild-to-moderate OSA9829.7 ± 19.2937.5 ± 7.8− 21.7 ± 18.1\< 0.0001 Women, severe OSA1946.9 ± 18.7179.3 ± 9.3− 33.8 ± 17.6\< 0.0001NS Men, severe OSA7949.5 ± 23.27721.4 ± 22.9− 27.2 ± 27.2\< 0.0001Non-supine AHI, /h Women, mild-to-moderate OSA229.7 ± 10.8223.3 ± 4.8− 6.3 ± 10.00.0008NS Men, mild-to-moderate OSA4611.7 ± 12.2513.4 ± 4.5− 8.3 ± 13.2\< 0.0001 Women, severe OSA1020.5 ± 21.095.6 ± 4.1− 17.7 ± 25.6NSNS Men, severe OSA5426.3 ± 19.34311.5 ± 16.4− 16.2 ± 15.5\< 0.0001Time in supine position, min Women, mild-to-moderate OSA25220 ± 9621232 ± 121− 26 ± 87NS0.033 Men, mild-to-moderate OSA53159 ± 9949192 ± 10826 ± 1260.032 Women, severe OSA11254 ± 13310199 ± 157− 113 ± 1050.0160.008 Men, severe OSA58212 ± 11146219 ± 11112 ± 112NSTime in non-supine position, min Women, mild-to-moderate OSA25214 ± 14321213 ± 12122 ± 86NSNS Men, mild-to-moderate OSA52270 ± 9549229 ± 114− 27 ± 130NS Women, severe OSA9137 ± 929173 ± 12878 ± 105NS0.061 Men, severe OSA57205 ± 12446204 ± 114− 23 ± 120NSValues are mean ± standard deviation*AHI* apnea-hypopnea index, *AI* apnea index, *HI* hypopnea index, *Mild-to-moderate* AHI 5--30/h, *NS* not statistically significant, *Severe* AHI \> 30/h

The ESS score decreased significantly during MRD therapy (from 10.6 ± 5.3 to 7.5 ± 4.4 in women and 11.4 ± 4.7 to 7.9 ± 4.3 in men; *p* \< 0.0001) with no sex differences. Excessive daytime sleepiness improved in 62% of men and women. Most clinical symptoms improved significantly in men and women after 3--6 months of MRD treatment; snoring disappeared in 53% of women and 48% of men. Self-reported symptoms, including sleep quality, awakening, nocturia, libido disorders, and mouth breathing, improved similarly in women and men. However, reduction of morning headache was more pronounced in women vs. men (*p* = 0.05). Mean total and domain scores on the QSQ significantly improved from baseline under MRD treatment (+ 24%, *p* \< 0.0001), and were similar in men and women. The Pichot fatigue scale score also improved significantly and similarly in men and women (− 35%, *p* \< 0.0001).

Among the 149 patients who underwent PSG, there were no significant changes in total sleep time, sleep latency, N1 + N2 sleep, slow wave sleep, rapid eye movement sleep duration, and wake duration during sleep from baseline to follow-up, and no differences between women and men. Arousals decreased to a similar extent in men and women (*p* \< 0.0001 vs. baseline). Women slept less in the supine position during MRD therapy compared with baseline (Table [2](#Tab2){ref-type="table"}); this was more marked in severe OSA (Table [3](#Tab3){ref-type="table"}).

Other parameters {#Sec12}
----------------

Body weight, BMI, blood pressure, and neck/waist circumference did not change significantly during MRD use, apart from a significant increase in waist circumference in men (1.34 ± 5.63 cm, *p* = 0.0003 vs. baseline).

Factors predictive of MRD efficacy {#Sec13}
----------------------------------

Model 1 (whole population) identified two significant independent predictors of MRD treatment success: initial AI and overbite, with no interactions by gender. A 10/h decrease in AI and a 1-mm increase in overbite were associated with a 41 and 43% increase in the number of MRD responders, respectively. No significant predictors of complete response in the overall patient population were identified. For models 2 (men) and 3 (women), univariate analysis identified a number of significant predictive factors (Table [4](#Tab4){ref-type="table"}). Significant independent predictors of MRD treatment success are summarized in Table [5](#Tab5){ref-type="table"}. In men, a 10/h decrease in AI and a 1-mm increase in overbite were associated with a 50 and 48% increase in the number of MRD responders, respectively. In women, treatment success probability was increased by 27% by a 1-mm increase in mandibular advancement. The similarity of independent predictors of treatment success overall and in men is probably due to the fact that men made up 75% of the total study population. For complete response, significant independent predictors included AHI in men, and neck circumference and no previous CPAP therapy in women (Table [5](#Tab5){ref-type="table"}).Table 4Univariate analysis of factors predicting therapy success and complete response (AHI \< 10/h) in men and womenVariableOR (95% CI)*p* valueTreatment success, men Neck circumference (cm)0.88 (0.78; 0.99)0.033 Waist circumference (cm)0.95 (0.92; 0.98)0.001 Obesity0.30 (0.12; 0.75)0.01 Dental class (class II vs. I)3.45 (1.16; 10.25)0.07 Dental class (class III vs. I)1.63 (0.34; 7.88)0.07 Overbite (mm)1.51 (1.19; 1.89)0.0005 Maximum mandibular advancement (mm)1.18 (1.03; 1.37)0.02 Overjet (mm)1.32 (1.06; 1.65)0.01 Initial AHI (/h)0.97 (0.95; 0.98)0.0013 Initial AI (/h)0.95 (0.93; 0.98)\< 0.0001 Initial supine AHI (/h)0.98 (0.97; 0.99)0.02 Mouth breathing (yes/no)2.14 (0.96; 4.74)0.06Complete response, men Neck circumference (cm)0.81 (0.72; 0.91)0.0003 Waist circumference (cm)0.94 (0.92; 0.97)0.0002 Neck circumference/waist circumference ratio∞ (0.91;∞)0.05 Obesity0.24 (0.10; 0.58)0.037 Dental class (class II vs. I)2.45 (1.09; 5.51)0.07 Dental class (class III vs. I)1.84 (0.47; 7.22)0.07 Overbite (mm)1.39 (1.15; 1.67)0.0007 Overjet (mm)1.19 (0.99; 1.43)0.06 Initial AHI (/h)0.91 (0.89; 0.94)\< 0.0001 Initial AI (/h)0.91 (0.89; 0.94)\< 0.0001 Initial HI (/h)0.96 (0.93; 0.99)0.006 Initial supine AHI (/h)0.96 (0.94; 0.98)\< 0.0001 No previous treatment by CPAP (yes/no)3.24 (1.77; 5.95)0.0001 Mouth breathing (yes/no)1.77 (0.91;3.44)0.094Treatment success, women Vertical dimension (mm)1.18 (1.00; 1.39)0.05 Maximum mandibular advancement (mm)1.73 (1.08; 2.78)0.02 Mandibular advancement (%)0.97 (0.94; 0.99)0.03 Initial AHI (/h)1.10 (1.01; 1.21)0.03 Initial HI (/h)1.11 (0.99; 1.24)0.07 Initial supine AHI (/h)1.07 (0.99; 1.16)0.08Complete response, women Neck circumference (cm)0.83 (0.68; 1.03)0.089 Mandibular advancement (%)0.98 (0.96; 1.0)0.09 Initial AHI (/h)0.94 (0.89; 0.99)0.01 Initial AI (/h)0.94 (0.88; 1.0)0.05 Initial HI (/h)1.11 (0.99; 1.24)0.07 No previous CPAP treatment (yes/no)7.64 (1.87; 31.33)0.005*AHI* apnea-hypopnea index, *AI* apnea index, *HI* hypopnea indexTable 5Factors predicting short-term MRD efficacy on multivariate analysisOdds ratio95% CI*p* valueWhole populationSuccess Overbite1.431.09--1.870.0096 Baseline apnea index0.960.94--0.980.025MenSuccess Overbite1.481.16--1.880.0015 Baseline apnea index0.950.93--0.980.0002Complete response Baseline AHI0.910.88--0.93\< 0.0001WomenSuccess Maximum mandibular advancement1.721.07--2.770.0236Complete response Neck circumference0.750.58--0.960.0265 No previous CPAP therapy11.432.28--57.330.0031*AHI* apnea-hypopnea index, *CI* confidence interval, *Complete response* AHI \< 10/h, *CPAP* continuous positive airway pressure, *Success* ≥ 50% decrease in the AHI

Tolerability {#Sec14}
------------

At least one side effect was reported by 55% of women and 49% of men, with some significant sex differences (Table [6](#Tab6){ref-type="table"}); 12% of women and 7% of men discontinued MRD therapy for side effects (*p* = 0.017). Mouth or temporomandibular joint pain was responsible for 60% of treatment discontinuations (no difference between men and women).Table 6Side effects% PatientsWomenMen*p* valueEvents Tooth pain1815NS Temporomandibular joint pain2520NS Occlusion change1915NS Gum irritation21100.016 Hypersalivation or mouth dryness69NS Dental mobility or migration1250.045 MRD discontinuation1270.017 Severe side effects1513NS*MRD* mandibular repositioning device, *NS* not statistically significant

Discussion {#Sec15}
==========

To the best of our knowledge, few studies have compared MRD treatment efficacy in women and men. All patients showed good compliance with therapy, but the treatment success rate was higher in women than in men, particularly in severe OSA. Complete response was also more common in women vs. men, across a range of AHI thresholds.

Previous data on sex differences in MRD effectiveness have reported conflicting results. One prospective observational study suggested that MRD effectiveness was greater in women vs. men \[[@CR14]\], while data from a large retrospective cohort of OSA patients treated with an MRD did not find any link between sex and MRD treatment outcome \[[@CR15]\]. Better MRD efficacy in women in our OSA cohort could be related to anthropometric and OSA characteristics. At baseline, BMI, waist, and neck circumferences were significantly lower in women, and during MRD use there was a tendency for reduced BMI only in women and increased waist circumference only in men. Obesity is known to be different between genders, with more central obesity in men. In a sleep clinic sample of women with OSA, fat in the neck region had a direct influence on airway patency, explaining 33% of the between-sex variance in AHI \[[@CR16]\]. In addition, higher BMI has been associated with lower MRD efficacy in some studies \[[@CR17]\], particularly in men \[[@CR14]\], and neck circumference may also predict MRD effectiveness \[[@CR18]\]. This was confirmed in our study, where multiple regression analysis identified smaller neck circumference at baseline as a statistically significant independent predictor of MRD success in women. Men have a longer, softer oropharynx and a larger, fatter, more posterior tongue, increasing the probability of upper airway collapse \[[@CR19], [@CR20]\]. The upper airway in men was found to be more collapsible than that in equally overweight/obese women \[[@CR10]\]. These factors, not specifically investigated in our analysis, support a role for anthropomorphic and physiological factors in sex differences in the response to MRD treatment of OSA.

Several studies have reported a lower success rate with MRD therapy in patients with severe OSA \[[@CR17]\], but others have found similar response rates across all OSA severities \[[@CR11], [@CR21]\]. In our clinical sample, baseline OSA severity was similar in men and women and the proportion of patients with severe OSA was similar in the two groups, but treatment response in the severe OSA group was significantly better in women vs. men. Baseline AHI and HI were similar in men and women in our study, but AI was significantly lower in women. During MRD treatment, AI decreased significantly in men and women, but women continued to have a significantly lower AI. In patients with severe OSA, HI decreased to a significantly greater extent in women vs. men. The lower AI at baseline in women is consistent with data showing that middle-aged women have fewer apneic events compared with men of same age and BMI \[[@CR22], [@CR23]\]. A lower AI and larger decrease in HI contributed to the greater reduction in total respiratory events in women during MRD therapy. We have previously shown that both AI and HI were significant predictors of MRD treatment success in this population \[[@CR11]\]. However, when analyzing men and women separately, decreases in AI and AHI were only independent predictors of treatment success and complete response in men. This could indicate that, in contrast to men, MRD efficacy in women is independent of OSA severity at baseline.

In this study, positional OSA did not appear to be associated with MRD success in women because supine and non-supine AHI were similar at baseline and decreased significantly with no significant differences between women and men. Effects of MRD treatment on positional OSA are controversial. Several studies have suggested that supine OSA was a predictor of MRD efficacy \[[@CR24], [@CR25]\]. Others have reported that supine-dependent OSA predicted MRD treatment success after controlling for other factors, whatever the gender \[[@CR26]\] or only in men \[[@CR14]\], suggesting that positional OSA is less of an issue for women. In contrast, MRD efficacy was not affected by supine-dependent OSA in some studies \[[@CR17], [@CR27]\]. These conflicting results may be explained by the ability of different MRD devices to stabilize the lower jaw in a forward position during supine position sleep \[[@CR28]\]. Most, but not all, position-dependent OSA patients appear to maintain positional dependency during MRD therapy, so MRDs might provide additional therapeutic effect in terms of sleep position \[[@CR29]\]. This was the case in our population, with time spent in the dorsal position decreasing significantly during MRD treatment in women with severe OSA, and time in the non-dorsal position was significantly longer in women. In contrast, time in the dorsal position increased significantly in men. Less time spent in the dorsal position in women may also contribute to the greater AHI reduction and greater decrease in arousals for severe OSA women during MRD therapy in our analysis. It is well known that the dorsal position promotes respiratory events and lateral position is considered to be protective against apnea \[[@CR30]\].

OSA has a well-known deleterious impact on quality of life and functional status. When OSA severity and obesity are similar, women report lower health status than men \[[@CR31]\]. In this study, quality of life improved significantly, and to a similar extent, in men and women. Improvements in quality of life in women during MRD therapy are similar to those reported with CPAP \[[@CR32]\]. Daytime sleepiness and fatigue were also similarly improved in men and women during MRD therapy, irrespective of OSA severity, and sleep structure was maintained.

Baseline OSA symptom severity was similar in men and women, as has been reported previously \[[@CR33]\]. In contrast, sex differences in OSA symptoms and severity have also been documented. Women report typical OSA symptoms (e.g., snoring) less often than men and are more likely to report general symptoms (e.g., fatigue, headache) \[[@CR19], [@CR34]\]. In our study, MRD therapy significantly reduced key OSA symptoms in men and women, and reduced morning headache to a greater extent in women than in men. Although women had a higher rate of hypothyroidism at baseline, all were receiving treatment for this condition and the rate was similar to that reported in the general population \[[@CR34]\].

Mandibular advancement is associated with enlargement of the velo-pharynx and increased mandibular protrusion produces greater reductions in the AHI. We found no differences between men and women in the number of titration visits, degree of protrusion, and final mandibular advancement, but ability to protrude the mandible was an independent predictor of MRD treatment success in women only. However, it is interesting to note that a high percentage of women (42.9%) vs. men (21.2%) had type 2 angle malocclusion, irrespective of OSA severity. Greater overbite has been described as a significant predictor of treatment success, predisposing patients with class II division 2 malocclusions to a higher success rate \[[@CR35]\]. This could have contributed to the higher treatment success rate in women in our study. Women with no previous CPAP therapy, experiencing MRD as first treatment, had higher therapy success rates, suggesting that MRD may be the best treatment for women, even in severe OSA.

Side effects were relatively common, but most were not severe. In our study, women who experienced side effects were more likely to discontinue therapy than men. Careful dental examination before MRD therapy is recommended, especially in women, to improve tolerability and maximize treatment adherence.

This study had some limitations. The design was observational, and there was an imbalance in the number of men and women, consistent with existing OSA prevalence data. Menopausal status of women was not documented, but the number of women aged \> 60 years (when most women are post-menopausal) was low. PSG was performed in only 149 subjects and OSA severity by sleep stage was not documented so we could not determine whether these differed between women and men, as described previously \[[@CR9]\]. Study strengths include the lack of existing data in this area, and the inclusion and follow-up of patients by a multidisciplinary sleep and dental team. In addition, only CAD/CAM MRD devices were used and these were custom-made for each patient.

In conclusion, our results show that CAD/CAM MRD is an effective treatment option in women with OSA of any severity, particularly those with severe OSA, due to some specific OSA phenotypes in women. Predictors of treatment success varied between men and women. These gender-specific differences in the response to MRD treatment need to be taken into account when deciding on the most appropriate therapeutic strategy for an individual OSA patient.
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